A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Saved in:
| Title: | A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. |
|---|---|
| Authors: | Mooradian MJ; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Reuben A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Prieto PA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Hazar-Rethinam M; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Frederick DT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA., Nadres B; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Piris A; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Juneja V; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.; Harvard University and Massachusetts Institute of Technology, Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA.; Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA., Cooper ZA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Sharpe AH; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA.; Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA., Corcoran RB; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Flaherty KT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Lawrence DP; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Sullivan RJ; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. |
| Source: | Oncoimmunology [Oncoimmunology] 2018 Feb 01; Vol. 7 (5), pp. e1423172. Date of Electronic Publication: 2018 Feb 01 (Print Publication: 2018). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2162-4011 |
|---|---|
| DOI: | 10.1080/2162402X.2017.1423172 |
